SCHEDULE 13G/A: Vanguard Group Discloses 4.77% Passive Stake in Replimune Group Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.77% beneficial ownership stake in Replimune Group Inc. as of December 31, 2024.

Summary

• The Vanguard Group reported beneficial ownership of 3,595,848 shares of Replimune Group Inc. Common Stock.
• This ownership represents 4.77% of the total class of securities.
• The filing is an Amendment No. 2 to Schedule 13G, indicating an update to a previously disclosed stake.
• The event date requiring this filing was December 31, 2024.
• Vanguard holds sole dispositive power over 3,503,821 shares and shared dispositive power over 92,027 shares.
• Vanguard holds shared voting power over 41,502 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Replimune Group Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership by a large institutional investor, which is a standard regulatory filing and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• The presence of a major institutional investor like The Vanguard Group holding a significant stake (4.77%) can be viewed as a vote of confidence in the company's long-term prospects, even if passive.

Negatives

• The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, indicating a passive investment approach rather than an activist one that might push for strategic changes.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Replimune Group Inc.'s future performance or Vanguard's investment strategy beyond the current beneficial ownership.

Management Comments

• The Vanguard Group certified that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a standard regulatory disclosure by a large asset manager, The Vanguard Group, indicating its passive investment in Replimune Group Inc., a company in the biotechnology sector. Such disclosures are common and reflect the ongoing portfolio management activities of major institutional investors.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake in the company, confirming a passive investment approach.

Key Dates

Keywords

Replimune Group Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing